Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 4, 2007

Eiken Chemical and bioMerieux Enter into Business Collaboration

  • Eiken Chemical and bioMerieux signed an agreement by which some pre-poured media provided to bioMerieux customers in Japan will be replaced by those manufactured by Eiken.

    “Since our foundation, we have been developing and offering reagents for microbiological investigation in order to prevent infectious diseases and food contamination. Today, we also develop and offer a wide range of in vitro diagnostic products and, specifically, culture media, which contribute to progress in public health,” says Tetsuya Teramoto, president and CEO of Eiken.

    “We have now come to an agreement with bioMerieux, one of the largest global companies in this field, regarding service and distribution. This is a sign of recognition of the quality of our products on the Japanese market, and therefore, we will make every effort possible to ensure this collaboration is a success.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »